Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Class I Phosphatidylinositol 3-Kinases"" wg kryterium: Temat


Tytuł :
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Autorzy :
Corbaux P; Institut de cancérologie des hospices civils de Lyon, université Claude-Bernard Lyon 1, centre hospitalier Lyon sud, faculté de médecine Lyon-Sud, département d'oncologie médicale, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France. Electronic address: .
Sabatier R; Institut Paoli-Calmettes, Centre de recherche en cancérologie de Marseille, laboratoire d'oncologie prédictive, département d'oncologie médicale, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université, 13009 Marseille, France.
Pokaż więcej
Transliterated Title :
Nouvelles AMMs au niveau européen : alpélisib – cancer du sein RH+/HER2− métastatique avec mutation PIK3CA.
Źródło :
Bulletin du cancer [Bull Cancer] 2020 Oct; Vol. 107 (10), pp. 959-960. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji :
Letter
MeSH Terms :
Estrogens*
Progesterone*
Breast Neoplasms/*drug therapy
Carcinoma, Ductal, Breast/*secondary
Class I Phosphatidylinositol 3-Kinases/*analysis
Neoplasm Proteins/*analysis
Neoplasms, Hormone-Dependent/*drug therapy
Receptor, ErbB-2/*analysis
Receptors, Estrogen/*analysis
Receptors, Progesterone/*analysis
Thiazoles/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/chemistry ; Breast Neoplasms, Male/chemistry ; Breast Neoplasms, Male/drug therapy ; Carcinoma, Ductal, Breast/chemistry ; Carcinoma, Ductal, Breast/drug therapy ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Clinical Trials as Topic ; Drug Approval ; Drug Resistance, Neoplasm ; Female ; Fulvestrant/administration & dosage ; Humans ; Male ; Multicenter Studies as Topic ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasms, Hormone-Dependent/chemistry ; Thiazoles/administration & dosage
Opinia redakcyjna
Tytuł :
PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.
Autorzy :
Palma G; SSD Sperimentazione Animale, Istituto Nazionale Tumori Fondazione G. Pascale - IRCSS, Naples, Italy.
Pasqua T; Laboratory of Cellular and Molecular Cardiovascular Patho-Physiology, Department of Biology, Ecology and Earth Science, University of Calabria, Rende, Italy.
Silvestri G; Institute of Human Virology, Division of Infectious Agents and Cancer, University of Maryland School of Medicine, Baltimore, MD, United States.
Rocca C; Laboratory of Cellular and Molecular Cardiovascular Patho-Physiology, Department of Biology, Ecology and Earth Science, University of Calabria, Rende, Italy.
Gualtieri P; School of Specialization in Food Science, University of Rome 'Tor Vergata', Rome, Italy.
Barbieri A; SSD Sperimentazione Animale, Istituto Nazionale Tumori Fondazione G. Pascale - IRCSS, Naples, Italy.
De Bartolo A; Laboratory of Cellular and Molecular Cardiovascular Patho-Physiology, Department of Biology, Ecology and Earth Science, University of Calabria, Rende, Italy.
De Lorenzo A; Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome 'Tor Vergata', Rome, Italy.
Angelone T; Laboratory of Cellular and Molecular Cardiovascular Patho-Physiology, Department of Biology, Ecology and Earth Science, University of Calabria, Rende, Italy.; National Institute for Cardiovascular Research (INRC), Bologna, Italy.
Avolio E; School of Specialization in Food Science, University of Rome 'Tor Vergata', Rome, Italy.; Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome 'Tor Vergata', Rome, Italy.
Botti G; Scientific Director, Istituto Nazionale Tumori Fondazione G. Pascale - IRCSS, Naples, Italy.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Aug 21; Vol. 11, pp. 2094. Date of Electronic Publication: 2020 Aug 21 (Print Publication: 2020).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Betacoronavirus*
Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
Coronavirus Infections/*drug therapy
Drug Repositioning/*methods
Molecular Targeted Therapy/*methods
Pneumonia, Viral/*drug therapy
Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Antirheumatic Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Butyrophenones/pharmacology ; Butyrophenones/therapeutic use ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Coronavirus Infections/virology ; Humans ; Inflammation/drug therapy ; Inflammation/immunology ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/blood ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Piperidines/pharmacology ; Piperidines/therapeutic use ; Pneumonia, Viral/virology ; Purines/pharmacology ; Purines/therapeutic use ; Quinazolinones/pharmacology ; Quinazolinones/therapeutic use
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Autorzy :
Huang T; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Ren K; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Ding G; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Yang L; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Wen Y; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Peng B; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Wang G; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Wang Z; Department of Thoracic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong 518020, P.R. China.
Pokaż więcej
Źródło :
Oncology reports [Oncol Rep] 2020 Jun; Vol. 43 (6), pp. 1906-1914. Date of Electronic Publication: 2020 Mar 17.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Adenocarcinoma of Lung/*genetics
Class I Phosphatidylinositol 3-Kinases/*genetics
Lung Neoplasms/*genetics
MicroRNAs/*genetics
A549 Cells ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/metabolism ; Aged ; Cell Line, Tumor ; Cisplatin/pharmacology ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Neoplastic Cells, Circulating/drug effects ; Neoplastic Cells, Circulating/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Autorzy :
Martínez-Sáez O; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Chic N; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Pascual T; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Adamo B; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Vidal M; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
González-Farré B; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Pathology Department, Hospital Clinic of Barcelona, Villarroel 170, Barcelona, 08035, Spain.
Sanfeliu E; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Pathology Department, Hospital Clinic of Barcelona, Villarroel 170, Barcelona, 08035, Spain.
Schettini F; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; University of Napoles Federico II, Napoles, Italy.
Conte B; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Brasó-Maristany F; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Rodríguez A; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.
Martínez D; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.
Galván P; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.
Rodríguez AB; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.
Martinez A; University of Napoles Federico II, Napoles, Italy.
Muñoz M; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Prat A; Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain. .; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08035, Barcelona, Spain. .; SOLTI Breast Cancer Research Group, Barcelona, Spain. .
Pokaż więcej
Źródło :
Breast cancer research : BCR [Breast Cancer Res] 2020 May 13; Vol. 22 (1), pp. 45. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
Breast Neoplasms/*genetics
Breast Neoplasms/*pathology
Class I Phosphatidylinositol 3-Kinases/*genetics
Genetic Testing/*methods
Thiazoles/*therapeutic use
Breast Neoplasms/drug therapy ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Cohort Studies ; Databases, Genetic ; Disease-Free Survival ; Female ; Humans ; Molecular Targeted Therapy/methods ; Predictive Value of Tests
Czasopismo naukowe
Tytuł :
Activated PI3Kδ breaches multiple B cell tolerance checkpoints and causes autoantibody production.
Autorzy :
Lau A; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.
Avery DT; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Jackson K; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Lenthall H; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Volpi S; Clinica Pediatrica e Reumatologia, Centro per le malattie Autoinfiammatorie e Immunodeficienze, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini and Dipartimento di Neuroscienze, riabilitazione, oftalmologia, genetica e scienze materno-infantili (DINOGMI), Università degli Studi di Genova, Genova, Italy.
Brigden H; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Russell AJ; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Bier J; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.
Reed JH; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.
Smart JM; Department of Allergy and Immunology, Royal Children's Hospital Melbourne, Victoria, Australia.
Cole T; Department of Allergy and Immunology, Royal Children's Hospital Melbourne, Victoria, Australia.
Choo S; Department of Allergy and Immunology, Royal Children's Hospital Melbourne, Victoria, Australia.
Gray PE; School of Women's and Children's Health, UNSW Sydney, Sydney, Australia.; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.
Berglund LJ; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.; Immunopathology Department, Westmead Hospital, Westmead, New South Wales, Australia.; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Hsu P; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.; Children's Hospital at Westmead, New South Wales, Australia.
Wong M; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.; Children's Hospital at Westmead, New South Wales, Australia.
O'Sullivan M; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.; Department of Immunology and Allergy, Princess Margaret Hospital, Subiaco, Western Australia, Australia.
Boztug K; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.; St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
Meyts I; Department of Immunology and Microbiology, Inborn Errors of Immunity, Department of Pediatrics, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Uzel G; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Notarangelo LD; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Brink R; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.
Goodnow CC; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.; UNSW Cellular Genomics Futures Institute, UNSW Sydney, Sydney, Australia.
Tangye SG; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.
Deenick EK; Immunity and Inflammatory Diseases, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; Clinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.; Faculty of Medicine, UNSW Sydney, Sydney, Australia.
Pokaż więcej
Źródło :
The Journal of experimental medicine [J Exp Med] 2020 Feb 03; Vol. 217 (2).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Gain of Function Mutation*
Antibody Formation/*genetics
Autoantibodies/*immunology
Class I Phosphatidylinositol 3-Kinases/*genetics
Immune Tolerance/*immunology
Plasma Cells/*immunology
Animals ; Autoantibodies/blood ; Autoantigens/immunology ; Autoimmunity/genetics ; Class I Phosphatidylinositol 3-Kinases/blood ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Female ; Germinal Center/immunology ; Humans ; Immunoglobulin M/blood ; Immunoglobulin M/immunology ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Signal Transduction/genetics
Czasopismo naukowe
Tytuł :
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis.
Autorzy :
Yu K; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Lin CJ; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Hatcher A; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA.
Lozzi B; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Kong K; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Huang-Hobbs E; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Cheng YT; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Beechar VB; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Zhu W; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Zhang Y; Dan L. Duncan Cancer Center, Division of Biostatistics, Baylor College of Medicine, Houston, TX, USA.
Chen F; Dan L. Duncan Cancer Center, Division of Biostatistics, Baylor College of Medicine, Houston, TX, USA.
Mills GB; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health Science University, Portland, OR, USA.
Mohila CA; Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Creighton CJ; Dan L. Duncan Cancer Center, Division of Biostatistics, Baylor College of Medicine, Houston, TX, USA.; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Noebels JL; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA.; Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, TX, USA.; Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
Scott KL; Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, TX, USA.
Deneen B; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA. .; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA. .; Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA. .
Pokaż więcej
Źródło :
Nature [Nature] 2020 Feb; Vol. 578 (7793), pp. 166-171. Date of Electronic Publication: 2020 Jan 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain Neoplasms/*enzymology
Class I Phosphatidylinositol 3-Kinases/*metabolism
Glioblastoma/*enzymology
Animals ; Brain Neoplasms/pathology ; Carcinogenesis/genetics ; Carcinogenesis/metabolism ; Class I Phosphatidylinositol 3-Kinases/chemistry ; Class I Phosphatidylinositol 3-Kinases/genetics ; Disease Models, Animal ; Glioblastoma/pathology ; Glypicans/metabolism ; Mice
Czasopismo naukowe
Tytuł :
(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
Autorzy :
Cao L; Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, China.
Dai C; Department of School Hospital, Changchun University of Chinese Medicine, Changchun, China.
Qin R; Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, China.
Guo Y; Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, China.
Liu J; Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, China.
Pokaż więcej
Źródło :
Immunopharmacology and immunotoxicology [Immunopharmacol Immunotoxicol] 2019 Dec; Vol. 41 (6), pp. 599-606. Date of Electronic Publication: 2019 Nov 06.
Typ publikacji :
Journal Article
MeSH Terms :
Class I Phosphatidylinositol 3-Kinases*/antagonists & inhibitors
Class I Phosphatidylinositol 3-Kinases*/immunology
Immunotherapy*
Neoplasms, Experimental*/immunology
Neoplasms, Experimental*/pathology
Neoplasms, Experimental*/therapy
Tumor Microenvironment*/drug effects
Tumor Microenvironment*/immunology
Antineoplastic Agents, Immunological/*pharmacology
Chromans/*pharmacology
Class Ib Phosphatidylinositol 3-Kinase/*immunology
Myeloid-Derived Suppressor Cells/*immunology
Neoplasm Proteins/*antagonists & inhibitors
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Animals ; Cell Line, Tumor ; Female ; Mice ; Myeloid-Derived Suppressor Cells/pathology ; Neoplasm Proteins/immunology ; Ovarian Neoplasms/immunology ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Programmed Cell Death 1 Receptor/immunology
Czasopismo naukowe
Tytuł :
Overview of the relevance of PI3K pathway in HR-positive breast cancer.
Autorzy :
Vasan N; Human Oncology and Pathogenesis Program, New York, USA; Departments of Medicine, New York, USA.
Toska E; Human Oncology and Pathogenesis Program, New York, USA.
Scaltriti M; Human Oncology and Pathogenesis Program, New York, USA; Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Dec; Vol. 30 Suppl 10, pp. x3-x11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Breast Neoplasms/*drug therapy
Breast Neoplasms/*metabolism
Class I Phosphatidylinositol 3-Kinases/*metabolism
Estrogen Receptor alpha/*metabolism
Protein Kinase Inhibitors/*therapeutic use
Proto-Oncogene Proteins c-akt/*metabolism
Animals ; Breast Neoplasms/pathology ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Class I Phosphatidylinositol 3-Kinases/genetics ; Drug Resistance, Neoplasm ; Estrogen Receptor alpha/antagonists & inhibitors ; Estrogen Receptor alpha/genetics ; Female ; Humans ; Molecular Targeted Therapy ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Proto-Oncogene Proteins c-akt/genetics ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Efficacy of PI3K inhibitors in advanced breast cancer.
Autorzy :
Verret B; Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.
Cortes J; IOB Institute of Oncology, Quiron, Madrid & Barcelona; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona; Medica Scientia Innovation Research (MedSIR), Valencia, Spain; Medica Scientia Innovation Research (MedSIR), New York, USA.
Bachelot T; Medical Oncology Department, Centre Léon Bérard, Lyon.
Andre F; Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France; Inserm Unit U981, Gustave Roussy Cancer Campus, Villejuif; Université Paris Sud, Paris-Saclay, France.
Arnedos M; Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France; Inserm Unit U981, Gustave Roussy Cancer Campus, Villejuif. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Dec; Vol. 30 Suppl 10, pp. x12-x20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
Animals ; Antineoplastic Agents/pharmacology ; Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Clinical Trials as Topic ; Female ; Humans ; Mutation ; Neoplasm Metastasis ; Protein Kinase Inhibitors/pharmacology ; Randomized Controlled Trials as Topic ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
PIK3CA in cancer: The past 30 years.
Autorzy :
Arafeh R; Weizmann Institute of Science, Rehovot, Israel.
Samuels Y; Weizmann Institute of Science, Rehovot, Israel. Electronic address: .
Pokaż więcej
Źródło :
Seminars in cancer biology [Semin Cancer Biol] 2019 Dec; Vol. 59, pp. 36-49. Date of Electronic Publication: 2019 Feb 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Class I Phosphatidylinositol 3-Kinases/*genetics
Class I Phosphatidylinositol 3-Kinases/*metabolism
Neoplasms/*etiology
Neoplasms/*metabolism
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Transformation, Neoplastic/genetics ; Cell Transformation, Neoplastic/metabolism ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Gain of Function Mutation ; Humans ; Molecular Targeted Therapy ; Mutation ; Neoplasms/drug therapy ; Neoplasms/pathology ; Phosphoinositide-3 Kinase Inhibitors/pharmacology ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Autorzy :
Tzanikou E; Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, University of Athens, Greece.
Markou A; Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, University of Athens, Greece.
Politaki E; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, Greece.
Koutsopoulos A; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, Greece.
Psyrri A; Oncology Unit, 2nd Department of Internal Medicine-Propaedeutic, Attikon University Hospital, Haidari, Greece.
Mavroudis D; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, Greece.
Georgoulias V; METROPOLITAN General Hospital, Athens, Greece.
Lianidou E; Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, University of Athens, Greece.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2019 Dec; Vol. 13 (12), pp. 2515-2530. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms*/blood
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Circulating Tumor DNA*/blood
Circulating Tumor DNA*/genetics
Class I Phosphatidylinositol 3-Kinases*/blood
Class I Phosphatidylinositol 3-Kinases*/genetics
Mutation, Missense*
Neoplastic Cells, Circulating*/metabolism
Neoplastic Cells, Circulating*/pathology
Amino Acid Substitution ; Female ; Humans ; MCF-7 Cells
Czasopismo naukowe
Tytuł :
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Autorzy :
Marqués M; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain. .; CIBERONC, Madrid, Spain.
Tranchant R; Centre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Université Paris Diderot, Sorbonne Université, USPC, Functional Genomics of Solid Tumors Team, Paris, France.
Risa-Ebrí B; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.
Suárez-Solís ML; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.; Department of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain.
Fernández LC; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.; Faculty of Biomedical Sciences and Health, Universidad Europea de Madrid, Madrid, Spain.
Carrillo-de-Santa-Pau E; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.; Computational Biology Group, Precision Nutrition and Cancer Research Program, IMDEA Food Institute, Madrid, Spain.
Del Pozo N; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.; CIBERONC, Madrid, Spain.
Martínez de Villarreal J; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.; CIBERONC, Madrid, Spain.
Meiller C; Centre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Université Paris Diderot, Sorbonne Université, USPC, Functional Genomics of Solid Tumors Team, Paris, France.
Allory Y; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.; Université Paris-Est Créteil, France INSERM, U955, Institut Mondor de Recherche Biomédicales AP-HP, Hôpital Henri Mondor, Department of Pathology, Créteil, France.
Blum Y; Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, Paris, France.
Pirker C; Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Hegedus B; Department of Thoracic Surgery, Medical of University Vienna, Vienna, Austria.
Barry ST; IMED Oncology, AstraZeneca, Li Ka Shing Centre, Cambridge, United Kingdom.
Carnero A; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain.; CIBERONC, Madrid, Spain.; Instituto de Biomedicina de Sevilla, IBIS/HUVR/Universidad de Sevilla/Consejo Superior de Investigaciones Científicas, Sevilla, Spain.
Berger W; Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Jean D; Centre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Université Paris Diderot, Sorbonne Université, USPC, Functional Genomics of Solid Tumors Team, Paris, France.
Real FX; Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain. .; CIBERONC, Madrid, Spain.; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2020 Feb 15; Vol. 80 (4), pp. 843-856. Date of Electronic Publication: 2020 Jan 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
Lung Neoplasms/*drug therapy
Mesothelioma/*drug therapy
Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors
Peritoneal Neoplasms/*drug therapy
Pleural Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzimidazoles/pharmacology ; Benzimidazoles/therapeutic use ; Cell Proliferation/drug effects ; Chromones/pharmacology ; Chromones/therapeutic use ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Disease Models, Animal ; Epithelium/pathology ; Female ; Gene Knock-In Techniques ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mesothelioma/genetics ; Mesothelioma/pathology ; Mice ; Mice, Knockout ; Mitogen-Activated Protein Kinase Kinases/metabolism ; Molecular Targeted Therapy/methods ; PTEN Phosphohydrolase/genetics ; Peritoneal Neoplasms/genetics ; Peritoneal Neoplasms/pathology ; Peritoneum/pathology ; Pleura/pathology ; Pleural Neoplasms/genetics ; Pleural Neoplasms/pathology ; Primary Cell Culture ; Prognosis ; Protein Kinase Inhibitors/therapeutic use ; Tumor Suppressor Protein p53/genetics
SCR Disease Name :
Mesothelioma, Malignant
Czasopismo naukowe
Tytuł :
Dysregulated actin dynamics in activated PI3Kδ syndrome.
Autorzy :
Wallace JG; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Zambrano-Rodas P; Facultad de Medicina, Universidad Nacional Mayor de San Marcos (UNMSM), Lima, Peru; Asociación para el Desarrollo de la Investigación en Ciencias de la Salud (ADIECS), Lima, Peru.
Córdova-Calderón W; Centro de Referencia Nacional de Asma, Alergia e Inmunología, Instituto Nacional de Salud del Niño, Breña, Peru.
Estrada-Turriate S; Facultad de Medicina, Universidad Nacional Mayor de San Marcos (UNMSM), Lima, Peru.
Mendoza-Quispe D; Facultad de Medicina, Universidad Nacional Mayor de San Marcos (UNMSM), Lima, Peru; Asociación para el Desarrollo de la Investigación en Ciencias de la Salud (ADIECS), Lima, Peru.
Limache Ontiveros Y; Servicio de Anatomía Patológica, Instituto Nacional de Salud del Niño, Breña, Peru.
Geha RS; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: .
Chou J; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Platt CD; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło :
Clinical immunology (Orlando, Fla.) [Clin Immunol] 2020 Jan; Vol. 210, pp. 108311. Date of Electronic Publication: 2019 Nov 21.
Typ publikacji :
Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Actin Cytoskeleton/*metabolism
Actins/*metabolism
Class I Phosphatidylinositol 3-Kinases/*metabolism
Skin/*pathology
Actin Cytoskeleton/genetics ; Apoptosis ; Cells, Cultured ; Child, Preschool ; Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Gain of Function Mutation/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Lymphopenia ; Necrosis ; Primary Immunodeficiency Diseases/genetics
SCR Disease Name :
Activated PI3K-delta Syndrome
Czasopismo naukowe
Tytuł :
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Autorzy :
Jeon HM; Pathology Center, Seegene Medical Foundation, Seoul, Republic of Korea.
Lee JS; Department of Pathology, Sungkyunkwan University School of Medicine, Samsung Changwon Hospital, Changwon, Republic of Korea.
Kim SH; Pathology Center, Seegene Medical Foundation, Seoul, Republic of Korea.
Yun KH; Yonsei Song-Dang Institute for Cancer Research, Yonsei University Health System, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Park KH; Yonsei Song-Dang Institute for Cancer Research, Yonsei University Health System, Seoul, Republic of Korea.
Jeon MK; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Lee YH; Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Yoon HI; Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Suh JS; Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hur H; Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim KS; Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim S; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim SH; Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim HS; Yonsei Song-Dang Institute for Cancer Research, Yonsei University Health System, Seoul, Republic of Korea, .; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, .
Pokaż więcej
Źródło :
Oncology [Oncology] 2020; Vol. 98 (11), pp. 817-826. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Journal Article
MeSH Terms :
B7-H1 Antigen/*biosynthesis
Class I Phosphatidylinositol 3-Kinases/*genetics
Liposarcoma/*genetics
Liposarcoma/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen/immunology ; Class I Phosphatidylinositol 3-Kinases/immunology ; Cohort Studies ; Female ; Gene Amplification ; Humans ; Immunohistochemistry ; Liposarcoma/pathology ; Liposarcoma/surgery ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/pathology ; Male ; Microsatellite Instability ; Middle Aged ; Mutation ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
miR-331-3p Inhibits Proliferation and Promotes Apoptosis of Nasopharyngeal Carcinoma Cells by Targeting elf4B-PI3K-AKT Pathway.
Autorzy :
Xuefang Z; Department of Radiotherapy, Dongguan People' Hospital, Dongguan, China.
Ruinian Z; Department of Medical Oncology, Dongguan People' Hospital, Dongguan, Guangdong, China.
Liji J; Department of Radiotherapy, Dongguan People' Hospital, Dongguan, China.
Chun Z; Department of Radiotherapy, Dongguan People' Hospital, Dongguan, China.
Qiaolan Z; Department of Journal Center, Third Affiliated Hospital of SUN YAT-SEN University, Guangzhou, China.
Jun J; Department of Medical Oncology, Dongguan People' Hospital, Dongguan, Guangdong, China.
Yuming C; Department of Radiotherapy, Dongguan People' Hospital, Dongguan, China.
Junrong H; Department of Radiotherapy, Dongguan People' Hospital, Dongguan, China.
Pokaż więcej
Źródło :
Technology in cancer research & treatment [Technol Cancer Res Treat] 2020 Jan-Dec; Vol. 19, pp. 1533033819892251.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Apoptosis*
Cell Proliferation*
Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
Eukaryotic Initiation Factors/*antagonists & inhibitors
MicroRNAs/*genetics
Nasopharyngeal Carcinoma/*pathology
Proto-Oncogene Proteins c-akt/*antagonists & inhibitors
Cell Line, Tumor ; Cell Movement ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Eukaryotic Initiation Factors/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Nasopharyngeal Carcinoma/genetics ; Nasopharyngeal Carcinoma/metabolism ; Nasopharyngeal Neoplasms/genetics ; Nasopharyngeal Neoplasms/metabolism ; Nasopharyngeal Neoplasms/pathology ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł :
Inhibition of PTEN Gene Expression by Small Interfering RNA on PI3K / Akt / FoxO3a Signaling Pathway in Human Nasopharyngeal Carcinoma.
Autorzy :
Yao LZ; Department of Otorhinolaryngology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Zhu YL; Department of Otorhinolaryngology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Liu JJ; Department of Otorhinolaryngology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Pokaż więcej
Źródło :
Technology in cancer research & treatment [Technol Cancer Res Treat] 2020 Jan-Dec; Vol. 19, pp. 1533033820917959.
Typ publikacji :
Journal Article
MeSH Terms :
Class I Phosphatidylinositol 3-Kinases/*metabolism
Forkhead Box Protein O3/*metabolism
Nasopharyngeal Neoplasms/*pathology
PTEN Phosphohydrolase/*genetics
Proto-Oncogene Proteins c-akt/*metabolism
RNA, Small Interfering/*genetics
Apoptosis/physiology ; Cell Line, Tumor ; Cell Movement/physiology ; Cell Proliferation/physiology ; Class I Phosphatidylinositol 3-Kinases/genetics ; Forkhead Box Protein O3/genetics ; Humans ; Nasopharyngeal Carcinoma/genetics ; Nasopharyngeal Carcinoma/metabolism ; Nasopharyngeal Carcinoma/pathology ; Nasopharyngeal Neoplasms/genetics ; Nasopharyngeal Neoplasms/metabolism ; PTEN Phosphohydrolase/antagonists & inhibitors ; PTEN Phosphohydrolase/biosynthesis ; PTEN Phosphohydrolase/metabolism ; Proto-Oncogene Proteins c-akt/genetics ; RNA, Small Interfering/administration & dosage ; RNA, Small Interfering/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł :
Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes.
Autorzy :
Xin T; Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, USA; Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China.
Han H; Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, USA; College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, Zhejiang Province, PR China.
Wu W; Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, USA; Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China.
Huang X; Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, USA; Department of Ophthalmology, Hainan Medical University, Haikou, Hainan Province, PR China.
Cui J; The University of British Columbia, Canada.
Matsubara JA; The University of British Columbia, Canada.
Song J; Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China.
Wang F; Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Colyer M; Department of Surgery, Walter Reed-Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Lei H; Shenzhen Eye Hospital, Shenzhen, Guangdong Province, PR China; Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, USA. Electronic address: .
Pokaż więcej
Źródło :
Experimental eye research [Exp Eye Res] 2020 Jan; Vol. 190, pp. 107884. Date of Electronic Publication: 2019 Nov 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
Enzyme Inhibitors/*pharmacology
Epiretinal Membrane/*drug therapy
Proto-Oncogene Proteins c-akt/*metabolism
Purines/*pharmacology
Quinazolinones/*pharmacology
Retinal Pigment Epithelium/*pathology
Vitreous Body/*metabolism
Blotting, Western ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Epiretinal Membrane/enzymology ; Fluorescent Antibody Technique, Indirect ; Humans ; Retinal Pigment Epithelium/enzymology ; Signal Transduction ; Vitreoretinopathy, Proliferative/drug therapy ; Vitreoretinopathy, Proliferative/enzymology
Czasopismo naukowe
Tytuł :
S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
Autorzy :
Yuan W; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Goldstein LD; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.; Department of Bioinformatics and Computational Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Durinck S; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.; Department of Bioinformatics and Computational Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Chen YJ; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Nguyen TT; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Kljavin NM; Department of Cancer Signaling, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Sokol ES; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, 02141, USA.
Stawiski EW; Research and Development Department, MedGenome Inc., Foster City, CA, 94404, USA.
Haley B; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Ziai J; Department of Pathology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Modrusan Z; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Seshagiri S; Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA. .; SciGenom Research Foundation, Bangalore, 560099, India. .
Pokaż więcej
Źródło :
Breast cancer research : BCR [Breast Cancer Res] 2019 Dec 27; Vol. 21 (1), pp. 152. Date of Electronic Publication: 2019 Dec 27.
Typ publikacji :
Journal Article
MeSH Terms :
Mammary Tumor Virus, Mouse*
Mutation*
Class I Phosphatidylinositol 3-Kinases/*metabolism
Mammary Neoplasms, Experimental/*etiology
Mammary Neoplasms, Experimental/*metabolism
S100 Calcium-Binding Protein A4/*metabolism
Tumor Suppressor Protein p53/*metabolism
Tumor Virus Infections/*complications
Animals ; Cell Line, Tumor ; Cell Transformation, Neoplastic ; Cell Transformation, Viral ; Class I Phosphatidylinositol 3-Kinases/genetics ; Disease Models, Animal ; Female ; Gene Targeting ; Humans ; Mammary Neoplasms, Experimental/pathology ; Mice ; Tumor Suppressor Protein p53/genetics ; Tumor Virus Infections/virology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer.
Autorzy :
Westbrook TC; Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Hagemann IS; Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Ley J; Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Chen K; Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Palka K; Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Liu J; Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Chen L; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.
Oppelt P; Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Adkins D; Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA. .; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. .
Pokaż więcej
Źródło :
Medical oncology (Northwood, London, England) [Med Oncol] 2019 Dec 21; Vol. 37 (2), pp. 12. Date of Electronic Publication: 2019 Dec 21.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Biomarkers, Tumor/*genetics
Class I Phosphatidylinositol 3-Kinases/*genetics
Head and Neck Neoplasms/*genetics
High-Throughput Nucleotide Sequencing/*methods
Neoplasm Recurrence, Local/*genetics
Adult ; Aged ; Biomarkers, Tumor/analysis ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Databases, Genetic ; Disease-Free Survival ; Female ; Head and Neck Neoplasms/pathology ; Humans ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/pathology ; Patient Selection ; Prospective Studies
Czasopismo naukowe
Tytuł :
Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells.
Autorzy :
Rodriguez R; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Fournier B; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Cordeiro DJ; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Winter S; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Izawa K; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Martin E; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Boutboul D; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Lenoir C; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Fraitag S; Department of Pathology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Kracker S; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.; Laboratory of Human Lymphohematopoiesis, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Watts TH; Department of Immunology, University of Toronto, Toronto, Canada.
Picard C; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.; Centre d'Etude des Déficits Immunitaires, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Bruneau J; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.; Department of Pathology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Callebaut I; Sorbonne Université, Muséum National d'Histoire Naturelle, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Paris, France.
Fischer A; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.; Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Collège de France, Paris, France.; Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Neven B; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.; Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Latour S; Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France .; University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Pokaż więcej
Źródło :
The Journal of experimental medicine [J Exp Med] 2019 Dec 02; Vol. 216 (12), pp. 2800-2818. Date of Electronic Publication: 2019 Sep 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Class I Phosphatidylinositol 3-Kinases/*deficiency
Epstein-Barr Virus Infections/*etiology
Herpesvirus 4, Human/*immunology
T-Lymphocytes/*immunology
T-Lymphocytes/*metabolism
Tumor Necrosis Factor Receptor Superfamily, Member 9/*deficiency
Virus Activation/*genetics
Virus Activation/*immunology
Class I Phosphatidylinositol 3-Kinases/chemistry ; Disease Susceptibility ; Epstein-Barr Virus Infections/diagnosis ; Germ-Line Mutation ; Histocytochemistry ; Homozygote ; Humans ; Immunophenotyping ; Loss of Function Mutation ; Lymphocyte Activation ; Lymphoproliferative Disorders/diagnosis ; Lymphoproliferative Disorders/etiology ; Lymphoproliferative Disorders/metabolism ; Models, Molecular ; Pedigree ; Phospholipase C gamma/metabolism ; Protein Conformation ; Proto-Oncogene Proteins c-akt ; Ribosomal Protein S6 Kinases/metabolism ; Sequence Analysis, DNA ; Signal Transduction ; Structure-Activity Relationship ; T-Lymphocytes/virology ; Tumor Necrosis Factor Receptor Superfamily, Member 9/chemistry
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies